Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

KURA Feb 16 '24 17.50 Call

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [N/A]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ rootItem.symbol ]]underlying price [[ rootItem.lastPrice ]] [[ rootItem.priceChange ]] ([[ rootItem.percentChange ]]) [[ rootItem.tradeTime ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Most Recent Stories

More News
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

SNDX : 20.66 (-4.04%)
ATNM : 6.96 (-3.33%)
KURA : 20.58 (-2.92%)
BMEA : 4.43 (+0.23%)
JNJ : 146.03 (-0.28%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

SNDX : 20.66 (-4.04%)
ATNM : 6.96 (-3.33%)
KURA : 20.58 (-2.92%)
BMEA : 4.43 (+0.23%)
JNJ : 146.03 (-0.28%)
2 Incredible Growth Stocks to Buy Hand Over Fist

These two healthcare growth stocks could have a lot more room to run.

KURA : 20.58 (-2.92%)
HIMS : 21.21 (-0.98%)
Kura Oncology: Q1 Earnings Snapshot

Kura Oncology: Q1 Earnings Snapshot

KURA : 20.58 (-2.92%)
Kura Oncology: Q4 Earnings Snapshot

Kura Oncology: Q4 Earnings Snapshot

KURA : 20.58 (-2.92%)
Kura Oncology (KURA) Offers Speculators a Profit-Scalping Opportunity

With bullish traders anticipating a quick pop in KURA stock, outside observers need to pay attention, especially because of the underlying short position.

KURA : 20.58 (-2.92%)
KURA|20240216|17.50C : N/A (N/A)
Kura Oncology: Q3 Earnings Snapshot

Kura Oncology: Q3 Earnings Snapshot

KURA : 20.58 (-2.92%)
Kura Oncology: Q2 Earnings Snapshot

Kura Oncology: Q2 Earnings Snapshot

KURA : 20.58 (-2.92%)
7 Best Cancer Stocks to Invest in Now

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

EXEL : 22.15 (-0.45%)
GILD : 68.40 (-0.35%)
NVS : 106.44 (-0.09%)
ON : 72.92 (+5.41%)
PFE : 27.83 (-1.38%)
MDCO : 84.90 (-0.07%)
MRK : 127.72 (-0.14%)
KURA : 20.58 (-2.92%)
AZN.LN : 12,094.000 (+0.07%)
BGNE : 143.93 (-0.66%)
Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data

June S&P 500 futures (ESM23) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.16% this morning as market participants braced for the Federal Reserve’s interest rate decision while...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
NVDA : 122.67 (-1.31%)
NXPI : 272.04 (+2.40%)
CMA : 51.12 (+0.63%)
BIIB : 228.82 (-1.27%)
LOGN.Z.IX : 86.060 (+1.25%)
ENT.LN : 636.300 (+2.86%)
PYPL : 58.97 (+2.01%)
CRWD : 385.05 (-1.81%)
MVIS : 1.0600 (+0.95%)
MIND : 4.17 (+0.24%)

Business Summary

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL,...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar